C9orf72 and amyotrophic lateral sclerosis: We expect this strategy to decrease expression of pathogenic RNAs and DPRs, as well as to spare most C9orf72 protein, and thereby address most of the major molecular mechanisms that are believed to underlie C9-ALS/FTD.